FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4254865375> ?p ?o ?g. }

• W4254865375 endingPage "347" @default.
• W4254865375 startingPage "345" @default.
• W4254865375 abstract "Children undergoing single-stage laryngotracheal reconstruction often receive neuromuscular blockers in the intensive care unit (ICU) to prevent dislodgment of the endotracheal tube and to facilitate healing of the graft (1). After several days, if direct visualization of the surgical site reveals acceptable anatomy, the trachea can be extubated as soon as the patient is awake and strong. Thus, it is appropriate to titrate sedatives and neuromuscular blockers so that their effects are minimal at that time. We present the case of a 3-yr-old who received vecuronium for 4 days after laryngotracheal reconstruction. Significant unexpected neuromuscular block was documented during direct laryngoscopy and tracheoscopy without further administration of a neuromuscular blocker. Case Report A 3-yr-old, 10.3-kg male child underwent repair of subglottic stenosis by single-stage laryngotracheal reconstruction. His medical history included birth at 34 wk gestation, reactive airway disease, gastroesophageal reflux, complete repair of Tetralogy of Fallot, and DiGeorge syndrome (abnormal development of the fourth branchial arch and derivatives of the third and fourth pharyngeal pouches resulting in abnormalities of the thymus, parathyroid, and great vessels). Physical examination revealed slight stridor and sternotomy scar. There was no hepatic or renal impairment. Postoperatively he received infusions of fentanyl 20 μg/hr, and vecuronium 2.43 μg · kg−1 · min−1 with intermittent boluses of fentanyl, midazolam, and clindamycin. On the second and third days in the ICU, the vecuronium infusion was stopped temporarily. Spontaneous movement was noted within 2 h. Vecuronium was then continued at the same rate to prevent spontaneous movement. At this rate of infusion of blocker, there were less than 5 responses to 1 Hz stimulation after 5 s of 50 Hz stimulation. After 4 days of vecuronium infusion, the drug was discontinued. Propofol was given while the ulnar nerve was stimulated at 2 Hz for 2 s at 60-s intervals and the train-of-four ratio (T4/T1, ratio of the amplitude of the fourth to the first response of the evoked electromyogram of the adductor pollicis) was recorded with a Neuromuscular Transmission Monitor (Datex, Helsinki, Finland). Until 10 h after termination of vecuronium T4/T1 was <0.4. The interval in which the T4/T1 was between 0.4 and 0.7 was 10 h. The interval in which the T4/T1 was between 0.7 and 0.9 was 4 h. Twenty-eight hours after discontinuation of the infusion of vecuronium, T4/T1 was 1.0, and the patient was then taken to the operating room. This was on the seventh day after beginning vecuronium infusion. The child received sevoflurane and nitrous oxide for bronchoscopy before attempted extubation. The larynx and trachea were sprayed with 3 mL of 1% lidocaine. After 20 min of 2.0% to 2.5% sevoflurane, sevoflurane was increased to 3% for 5 min. At that time the initial response to the train-of-four stimuli had decreased to 75% of what it had been on entry to the operating room and T4/T1 was 0.33 (Fig. 1). This nadir of neuromuscular function occurred 25 min after beginning sevoflurane. After conclusion of endoscopy, an orotracheal tube was placed. Fifteen minutes after stopping sevoflurane administration the T4/T1 was more than 0.7. The patient returned to the ICU. Tracheal extubation was successful 3 h later when the ICU physicians judged he was ready (2).Figure 1: Time is increasing from left to right on the x-axis. Minutes since beginning the record are noted on the top of the graph. Neuromuscular function (as % of baseline) is increasing with elevation of the y-axis. When the first response is equal to the fourth response to a train-of-four stimulation, a solid black mark is displayed. As the fourth response decreases, the first response is seen as the thin black line above the solid black area that indicates the fourth response.Plasma was obtained for measurement of vecuronium and 3-OH-vecuronium (3). The concentrations of 3-OH-vecuronium/vecuronium were 45/450 ng/mL on the second day, 96/529 ng/mL on the fourth day of infusion of vecuronium, and 13/27 ng/mL 24 h after termination of the infusion. Clearance of vecuronium, estimated by dividing infusion rate, 2.43 μg · kg−1 · min−1, by the measured plasma concentrations, was 5.4 mL · kg−1 · min−1 and 4.6 mL · kg−1 · min−1. Discussion This case emphasizes that the patient who has received vecuronium and antibiotics for days in the ICU may be particularly sensitive to the neuromuscular effects of drugs administered during anesthesia. The anesthetic course of this patient suggests that quantitative monitoring of neuromuscular function is prudent in such situations. If the neuromuscular block present at the end of the diagnostic procedure had been unrecognized in this case and the endotracheal tube had been removed, it is likely that airway function would have been compromised. Previous observations without quantitative monitoring (4) have suggested that recovery from block would be faster in this case, yet some residual neuromuscular block could still be present. For example, without quantitative monitoring, a T4/T1 between 0.4 (5) and 0.9 cannot be detected. Recovery of evoked neuromuscular function of the adductor pollicis to a T4/T1 of >0.7 has been considered synonymous with recovery of upper airway and respiratory function (6). However, weakness of the masseter, orbicularis oris, speech, and grip strength persist until the T4/T1 reaches 0.9 (7). Therefore the patient may experience upper airway dysfunction (8) as a result of residual block when block is difficult to detect. After infusion of vecuronium for days, neuromuscular function had recovered to the most stringent criteria when our patient entered the operating room for bronchoscopy. Nevertheless, the drugs he received for anesthesia produced a clinically significant, but manually undetectable, degree of block. There could be several reasons why recovery was so slow. When accelerometry was used to titrate vecuronium infusion to maintain one response to train-of-four stimuli, the infusion rate was 50% less than was given to this child and spontaneous recovery occurred more quickly (9). This child received a higher infusion rate. Clearance of vecuronium in this patient was not significantly different from that measured during general anesthesia after a short infusion of vecuronium at the same rate given to this patient (10). This suggests that the volume of distribution of vecuronium increased with continued exposure to the drug. However, in six adult ICU patients, steady-state volume of distribution of vecuronium did not change significantly over 3–6 days (11). Clindamycin may potentiate block (12,13) and has been associated with slower spontaneous recovery from doxacurium in similar patients (14). Sevoflurane (15) and lidocaine (16) can augment block. The plasma concentration of lidocaine after tracheal spray could be 2.5 to 3.0 μg/mL (17). Whichever drugs significantly enhanced the block, it is not surprising that a significant increase in depth of block was noted in this case, given the slow spontaneous recovery from vecuronium. The presence of T4/T1 of 1.0 does not preclude the presence of residual block at higher stimulation frequency (18). Another reason for slow recovery is that the metabolite of vecuronium, 3-OH-vecuronium, probably contributed to the block after the end of the infusion. The C50 of vecuronium and 3-OH-vecuronium is 102 ng/mL and 123 ng/mL respectively (19). Thus 3-OH-vecuronium has 80% of the potency of its parent compound, vecuronium. Furthermore, the kinetics of these two compounds differ. The plasma clearance of 3-OH vecuronium is less than that of vecuronium, and its steady-state volume of distribution is larger, resulting in a longer terminal half-life and mean residence time (19). Although persistence of 3-OH-vecuronium has been noted in two patients with decreased creatinine clearance (20,21), this has not been observed previously in a patient with normal renal function." @default.
• W4254865375 created "2022-05-12" @default.
• W4254865375 creator A5012339527 @default.
• W4254865375 creator A5041400311 @default.
• W4254865375 creator A5069713109 @default.
• W4254865375 date "2001-08-01" @default.
• W4254865375 modified "2023-09-28" @default.
• W4254865375 title "Unmasked Residual Neuromuscular Block After Administration of Vecuronium for Days" @default.
• W4254865375 cites W1968304427 @default.
• W4254865375 cites W1980142618 @default.
• W4254865375 cites W1991433201 @default.
• W4254865375 cites W1998948832 @default.
• W4254865375 cites W2007977214 @default.
• W4254865375 cites W2010104949 @default.
• W4254865375 cites W2010715488 @default.
• W4254865375 cites W2030202101 @default.
• W4254865375 cites W2037231475 @default.
• W4254865375 cites W2039575002 @default.
• W4254865375 cites W2045332614 @default.
• W4254865375 cites W2057524299 @default.
• W4254865375 cites W2061778695 @default.
• W4254865375 cites W2064317329 @default.
• W4254865375 cites W2090458735 @default.
• W4254865375 cites W2143756980 @default.
• W4254865375 cites W2150976323 @default.
• W4254865375 cites W2156327163 @default.
• W4254865375 cites W2337599582 @default.
• W4254865375 cites W4253019490 @default.
• W4254865375 doi "https://doi.org/10.1213/00000539-200108000-00021" @default.
• W4254865375 hasPublicationYear "2001" @default.
• W4254865375 type Work @default.
• W4254865375 citedByCount "2" @default.
• W4254865375 crossrefType "journal-article" @default.
• W4254865375 hasAuthorship W4254865375A5012339527 @default.
• W4254865375 hasAuthorship W4254865375A5041400311 @default.
• W4254865375 hasAuthorship W4254865375A5069713109 @default.
• W4254865375 hasBestOaLocation W42548653751 @default.
• W4254865375 hasConcept C11413529 @default.
• W4254865375 hasConcept C155512373 @default.
• W4254865375 hasConcept C206044474 @default.
• W4254865375 hasConcept C2524010 @default.
• W4254865375 hasConcept C2776184885 @default.
• W4254865375 hasConcept C2777210771 @default.
• W4254865375 hasConcept C2909465803 @default.
• W4254865375 hasConcept C33923547 @default.
• W4254865375 hasConcept C41008148 @default.
• W4254865375 hasConcept C42219234 @default.
• W4254865375 hasConcept C71924100 @default.
• W4254865375 hasConceptScore W4254865375C11413529 @default.
• W4254865375 hasConceptScore W4254865375C155512373 @default.
• W4254865375 hasConceptScore W4254865375C206044474 @default.
• W4254865375 hasConceptScore W4254865375C2524010 @default.
• W4254865375 hasConceptScore W4254865375C2776184885 @default.
• W4254865375 hasConceptScore W4254865375C2777210771 @default.
• W4254865375 hasConceptScore W4254865375C2909465803 @default.
• W4254865375 hasConceptScore W4254865375C33923547 @default.
• W4254865375 hasConceptScore W4254865375C41008148 @default.
• W4254865375 hasConceptScore W4254865375C42219234 @default.
• W4254865375 hasConceptScore W4254865375C71924100 @default.
• W4254865375 hasIssue "2" @default.
• W4254865375 hasLocation W42548653751 @default.
• W4254865375 hasLocation W42548653752 @default.
• W4254865375 hasOpenAccess W4254865375 @default.
• W4254865375 hasPrimaryLocation W42548653751 @default.
• W4254865375 hasRelatedWork W1965407822 @default.
• W4254865375 hasRelatedWork W1995421842 @default.
• W4254865375 hasRelatedWork W2015090983 @default.
• W4254865375 hasRelatedWork W2074666562 @default.
• W4254865375 hasRelatedWork W2141271305 @default.
• W4254865375 hasRelatedWork W2148210097 @default.
• W4254865375 hasRelatedWork W2356897053 @default.
• W4254865375 hasRelatedWork W2406922366 @default.
• W4254865375 hasRelatedWork W2407646270 @default.
• W4254865375 hasRelatedWork W2410359091 @default.
• W4254865375 hasVolume "93" @default.
• W4254865375 isParatext "false" @default.
• W4254865375 isRetracted "false" @default.
• W4254865375 workType "article" @default.